Beximco Pharma's H1 profit jumps 18% to Tk353cr
During the period, its profit jumped by 18% to Tk353.50 crore compared to the previous year at the same time
Beximco Pharmaceuticals' profit grew 18% year-on-year to Tk353 crore in the first half of the current fiscal year, according to a stock exchange filing.
Its revenue surged 9% to Tk2,401 crore, while earnings per share (EPS) stood at Tk7.87. Despite robust growth, its shares dropped 1.83% to close at Tk75.20 on the Dhaka Stock Exchange (DSE).
In the October-December quarter, the drugmaker's revenue rose 13% to Tk1,230 crore, while profit grew 28% to Tk184 crore.
Keep updated, follow The Business Standard's Google news channel
Iqbal Ahmed, managing director of Beximco Pharma, commented on the filing on the London Stock Exchange, saying, "We are pleased to announce our second-quarter and half-year results, demonstrating strong, profitable growth despite ongoing macroeconomic challenges."
"We have launched new products domestically and expanded our international presence through new product registrations and entry into new export markets. We look forward to sustaining this momentum in the second half of the fiscal year while continuing to provide essential medicines to patients worldwide," he added.
